MHRA paediatric investigation plan
Borrelia outer surface protein A (OspA) serotypes (ST1-6) lipidated, fusion protein vaccine (VLA15 - PF-07307405) (Borrelia outer surface protein A (OspA) serotypes (ST1-6) lipidated, fusion protein vaccine (VLA15 - PF-07307405))
MHRA paediatric investigation plan MHRA-101091-PIP01-23 · Agreement
Key facts
| PIP number | MHRA-101091-PIP01-23 |
|---|---|
| Active substances | Borrelia outer surface protein A (OspA) serotypes (ST1-6) lipidated, fusion protein vaccine (VLA15 - PF-07307405) |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of Lyme disease |
| Decision | P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) |
| Published | Feb 11, 2025 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: